AIRS Medical, a Seoul, South Korea-based healthcare startup and a member of the Born2Global Centre, recently announced that it has raised approximately $20 million in Series B funding.
The round of Series B funding welcomed new investors Q Capital Partners and Hanwha Life and additional funds from Klim Ventures, which had contributed to the startup's Series A funding.
Through the Series B funding, AIRS Medical will take its innovative diagnostic solutions to the global market.
Company: AIRS Medical Inc.
Round: Series B
Funding Month: Aug 2022
Lead Investors: Q Capital Partners and Hanwha Life
Additional Investors: Klim Ventures
Company Website: https://en.airsmed.com/
Software Category: Medical AI
About the Company: Founded in October 2018, AIRS Medical Inc., is a medical AI startup based in Seoul, Korea, that develops innovative products and services to improve patient experience and achieve greater institutional efficiency in areas in which a lack of productivity limits clinical value. AIRS Medical is a startup that uses digitalized, AI-based diagnostic tests and robotics technologies to provide a better clinical experience for both patients and healthcare providers. AIRS Medical has been recognized for its deep learning MR image reconstruction technology, winning both the 2019 and 2020 fastMRI Challenge co-hosted by Facebook AI Research (FAIR) and NYU Langone Health. Following these wins, the startup successfully developed and commercialized its technology, called SwiftMR™, and has been using it to benefit the broader healthcare community. In March 2022, AIRS Medical acquired artiQ, an AI- and robotics-based startup that shared AIRS Medical's vision of a world without any sickness. Using its talent and technology, AIRS Medical aims to deliver medical services that can benefit a wider community.